| Name | Fluconazole |
| Description | Fluconazole (UK-49858) belongs to the triazole class of antifungal agents and is a CYP51 inhibitor (IC99 = 0.20–0.39 μg/mL against Candida albicans), possessing broad-spectrum antifungal activity, good oral absorption, and cell permeability. This compound is used for the treatment of various invasive fungal infections. |
| In vitro | Methods: The in vitro antifungal activity of Fluconazole against clinically isolated Candida species was determined by CLSI M27-E4 broth microdilution method, with incubation for 24-48 hours.
Results: The MIC90 of Fluconazole against Candida albicans was 2 μg/mL, with a susceptibility rate of 92%; against Candida glabrata, the MIC90 was 16 μg/mL, with 98% showing dose-dependent susceptibility. The wild-type proportion of Fluconazole for recurrent VVC strains was significantly lower than other types (67% vs 77%).[1]
Methods: Broth microdilution method was used to determine the in vitro activity of Fluconazole against Candida. YPD medium was used, with Fluconazole concentrations ranging from 0-128 μg/mL (two-fold dilutions), inoculation of 2×10^5 CFU/mL Candida, and incubation at 30°C for 24 hours before MIC reading.
Results: Fluconazole showed good inhibitory effects against susceptible strains, but MIC values were significantly elevated against resistant strains.[2] |
| In vivo | Methods: A Galleria mellonella larval systemic infection model with Candida albicans was established. Fluconazole (20 μg/mL, 10 μL per larva, dissolved in DMSO) was administered by single injection 1.5-2 hours post-infection.
Results: Fluconazole monotherapy significantly prolonged the median survival time of infected larvae (9.33 days vs 2.33 days) and reduced fungal burden.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 30.6 mg/mL (99.91 mM), Sonication is recommended.
DMSO : 260 mg/mL (848.92 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.53 mM), Sonication is recommended.
|
| Keywords | UK49858 | UK 49858 | Triazole | kefyr | Inhibitor | inhibit | fungi,Candida | Fungal | Fluconazole | Candida | C. albicans | Antifungal | Antibiotic | albicans | Agent | 14-α Demethylase |
| Inhibitors Related | Neomycin sulfate | Calcium Propionate | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Benzyl propionate | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Fungal Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
